AIP
TYRA icon

Arrowpoint Investment Partners’s Tyra Biosciences TYRA Stock Holding History

Arrowpoint Investment Partners’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,075
Closed -$309K – 163
2026
Q1 		$309K Buy
+8,075
New +$261K 0.27% 58

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Arrowpoint Investment Partners's TYRA Position: Q2 2026 in Review

Arrowpoint Investment Partners sold out of Tyra Biosciences (TYRA) in Q2 2026, closing a stake of 8,075 shares — an estimated $309K sold.

Arrowpoint Investment Partners first reported a position in TYRA in Q1 2026 and held it in 1 quarter. The position peaked at $309K in Q1 2026. 168 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Arrowpoint Investment Partners reported no remaining Tyra Biosciences position as of Q2 2026 after selling out during the quarter.
  • Arrowpoint Investment Partners sold 8,075 Tyra Biosciences shares in Q2 2026, an estimated $309K.
  • Arrowpoint Investment Partners first reported a position in Tyra Biosciences in Q1 2026 and held it in 1 quarter.
  • Arrowpoint Investment Partners's Tyra Biosciences position peaked at $309K in Q1 2026.
  • 168 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.